| Info Sheets |
| | | | | | | | | | | | | | | | | | | | | | | | |
| Out- side |
| | | | |
|
| | | | |
Result : Searchterm 'Coronary Angiography' found in 2 terms [] and 5 definitions [], (+ 3 Boolean[] results
| previous 6 - 10 (of 10) Result Pages : [1] [2] | | | | Searchterm 'Coronary Angiography' was also found in the following services: | | | | |
| | |
| |
|
| | | | | | | | | • View the NEWS results for 'Heart MRI' (18).
| | | | Further Reading: | | Basics:
|
|
News & More:
| |
| |
| | | | | |
| |
|
The navigator technique measures with an additional quick MR prepulse the position, of e.g. the diaphragm before data collecting. Similar respiratory conditions of the patient can be identified and used to synchronize image data acquisition so that respiration induced image blurring is minimized by either respiratory ordered phase encoding or respiratory gating.
The prepulse sequence images a small area perpendicular to the structure, which is moving. The contrast of the interface between the diaphragm and the lung should be high to permit easy automatic detection.
After data acquisition, the position of the interface is automatically recorded and imaging data are only accepted when the position of the interface falls within a range of prespecified values.
This technique has the advantage of greater accuracy than other respiratory gating (therefore used for coronary angiography) and has no need for additional sensing MRI equipment, as the MR system itself provides it. | | | | • View the DATABASE results for 'Navigator Technique' (5).
| | | | |
| | | | | |
| |
|
Device Information and Specification
CLINICAL APPLICATION
Whole body
CONFIGURATION
Short bore compact
Standard: Head, body, cardiac, optional phased array: Spine, pediatric, 3rd party connector; Optional SENSE? coils for all applications
SE, Modified-SE, IR (T1, T2, PD), STIR, FLAIR, SPIR, FFE, T1-FFE, T2-FFE, Balanced FFE, TFE, Balanced TFE, Dynamic, Keyhole, 3D, Multi Chunk 3D, Multi Stack 3D, K Space Shutter, MTC, TSE, Dual IR, DRIVE, EPI, Cine, 2DMSS, DAVE, Mixed Mode; Angiography: Inflow MRA, TONE, PCA, CE MRA
128 x 128, 256 x 256,512 x 512,1024 x 1024 (64 for Bold img)
Variable in 1% increments
Lum.: 120 cd/m2; contrast: 150:1
Variable (op. param. depend.)
POWER REQUIREMENTS
380/400 V
| | | | • View the DATABASE results for 'Intera Achieva CV™' (2).
| | | | Further Reading: | News & More:
|
|
| |
| | | Searchterm 'Coronary Angiography' was also found in the following services: | | | | |
| | |
| |
|
MS-325 is the formerly code name of gadofosveset trisodium (new trade name Vasovist). MS-325 belongs to a new class of blood pool agents for magnetic resonance angiography ( MRA) to diagnose vascular disease. Gadofosveset trisodium has ten times the signal-enhancing power of existing contrast agents as well as prolonged retention in the blood. This enables the rapid acquisition of high resolution MRA's using standard MRI machines.
Gadofosveset trisodium, which is gadolinium-based, stays in the blood stream as a result of transient binding to albumin. Albumin binding offers an additional benefit beyond localization in the blood pool. The contrast agent begins to spin much more slowly, at the rate albumin spins, causing a relaxivity gain that produces a substantially brighter signal than would be possible with freely circulating gadolinium.
MS-325 is an intravascular contrast agent intended for use in MRI as an aid in diagnosing aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease (PVD) or abdominal aortic aneurysm (AAA).
Currently clinical trials completed for peripheral vascular disease and coronary artery disease. Additional trials are also being conducted to evaluate MS-325 as an aid in diagnosing breast cancer and suggested that it might be feasible to combine the use of MS-325, injected during peak stress, with delayed high-resolution imaging to identify myocardial perfusion defects.
Vasovist (MS-325) would compete with the contrast agents Ferumoxytol ( Code 7228) from AMAG Pharmaceuticals, Inc. and NC100150 Injection from Nycomed Amersham, but their further development is uncertain.
Partners in development: EPIX Pharmaceuticals, Inc., Mallinckrodt Inc., and Bayer Schering Pharma AG. Bayer Schering Pharma has the worldwide marketing rights for the product.
Formerly known under the Mallinckrodt trademark name, AngioMARK®.
See also Classifications, Characteristics, etc. | | | | • View the DATABASE results for 'MS-325' (4).
| | | • View the NEWS results for 'MS-325' (10).
| | | | Further Reading: | News & More:
|
|
| |
| | | | | |
| |
|
Vasovist™ is an albumin-targeted intravascular contrast agent. It is indicated for contrast enhanced MR angiography (CE-MRA) for the visualization of abdominal or limb vessels in patients with suspected or known vascular disease. After IV injection, Vasovist™ binds reversibly to human albumin in plasma, which results in long-lasting increased relaxivity. Imaging from 5 to 50 min is possible. A small unbound portion is, by glomerular filtration, eliminated by the kidneys.
AngioMARK® was the formerly trade name and MS-325 the research name. Currently the phase III clinical trials are completed to determine its efficacy for peripheral vascular disease and coronary artery disease.
In the U.S., EPIX received an approvable letter from the U.S. Food and Drug Administration (FDA) for Vasovist™ in January 2005. In 2009, Epix Pharmaceuticals has sold the U.S., Canadian and Australian rights for its blood pool agent (now named ABLAVAR™), to Lantheus Medical Imaging, Inc..
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m 2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or the liver transplantation period.
See also MRI Safety.
Drug Information and Specification NAME OF COMPOUND Diphenylcyclohexyl phosphodiester-Gd-DTPA, gadofosveset trisodium, MS-325 T1, predominantly positive enhancement 20-45 mmol-1sec-1, Bo=0,47T PHARMACOKINETIC Intravascular, short elimination half life CONCENTRATION 244 mg/mL, 0.25mmol/mL DOSAGE 0.12 mL/kg, 0.03 mmol/kg DEVELOPMENT STAGE approved DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information TERRITORY TRADE NAME DEVELOPMENT STAGE DISTRIBUTOR North America, Australia for sale | | | | • View the DATABASE results for 'Vasovist™' (7).
| | | | Further Reading: | Basics:
|
|
| |
| | | | |
| | previous 6 - 10 (of 10) Result Pages : [1] [2] |
| |
|
| |
| Look Ups |
| |